Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP

Exclusion Criteria

• •Unifocal forms of CIDP
• •Pure sensory CIDP
• •MMN with conduction block
• •Treatment of CIDP with immunoglobulins (intravenous or subcutaneous) at any time prior to study entry
• •Steroids of any type equivalent to prednisolone or prednisone \> 10 mg/day or equivalent plasma exchange (PE) during the last 3 months prior to baseline visit
• •Treatment with cyclosporin, methotrexate, mitoxantrone, mycophenolate mofetil, interferon or other immunosuppressive or immunomodulatory drugs during the three months prior to baseline visit
• •Clinical evidence of peripheral neuropathy from another
• •Known diabetes mellitus
• •Other serious medical condition complicating assessment or treatment
• •Thromboembolic events: patients with a history of deep vein thrombosis (DVT) within the last year prior to baseline visit or pulmonary embolism ever
• •Known IgA deficiency with antibodies to IgA
• •History of hypersensitivity, anaphylaxis or severe systemic response to immunoglobulin, blood or plasma derived products, or any component of NewGam
• •Known blood hyperviscosity